Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.

Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...

每经AI快讯，有投资者在投资者互动平台提问：请问吉利德是否为公司重要客户？有提供了哪些产品和服务吗？谢谢 九洲药业（603456.SH）9月20日在投资者互动平台表示，公司服务客户包括 ...

Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with ...

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...

周三，美银证券调整了对Novartis (NOVN:SW) (NYSE: NVS)股票的立场，将这家制药巨头的评级从买入下调至中性。该公司还修改了Novartis的目标价，将其从之前的110.00瑞士法郎下调至110.00瑞士法郎。这一评级变化是在Novartis相对于其欧洲制药同行表现出色之后做出的。 自2023年初以来，Novartis因一系列成功的III期试验和持续超出预期的盈利而备受关注， ...

New Novartis data in relapsing MS reinforce benefits of Kesimpta for first-line and switch patients: Basel Friday, September 20, 2024, 12:00 Hrs [IST] Novartis announced new data ...

Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.

Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Novartis AG (NOVN – Research Report) and keeping the price ...

Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that ...

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...